We are routinely approached by companies, shareholders and boards of directors telling us that their company was approached by a prospective buyer anxious to consummate a transaction. They may even have a non-binding indicative offer in hand – or expect one shortly. It can be exciting to have a sophisticated firm find your baby to be attractive – rewarding to be approached by a big potential buyer and it could be a load off your mind after years and years of hard work for a possible large payoff. But more often than not, we have found that one-off acquisition processes fail, or – at best – result in a sub-optimal deal. The examples are legion. The problems with these ad-hoc discussions are many.
Our latest M&A update on the recent transactions and values in the seven separate sectors of the fintech market that we follow and sometimes lead is HERE.
The report that follows HERE is our latest update on m&a values and trends in the dozen+ sectors of the information technology industry that we follow and sometimes lead. It’s too soon to tell how the consternation in the political world will affect this industry. High levels of liquidity and low interest rates help a lot, but uncertainty doesn’t. And while our sector remains fairly hot – see the report – overall m&a volume and value was clearly down in the first half of 2016 compared to the second half of 2015. Last year, m&a was torrid – with 39 mega deals valued at $10bn or more in the second half alone. So it’s not shocking to see overall m&a values and volume fall off a bit. Political consternation is a concern, however.
The first half of 2016 was the strongest on record for digital health companies. According to StartUp Health, there was nearly $4 billion invested in over 150 early stage deals. For 1H16, the top digital health investment category was patient/consumer experience at $958 million, or nearly 25% of invested capital. StartUp Health notes that over 7,600 startups around the world are working on digital health. And that’s just the startups.
The New Year started out with a bang for companies in all four segments of the Enterprise Data & Analytics space. More than a dozen transactions of significance were announced including deals by Bessemer, Bloomberg, IBM, Moody’s, Oracle and Thoma Bravo. EV-to-revenue multiples as well as EV-to-EBITDA multiples for all four segments remained relatively strong, despite a backdrop of volatility in the capital markets. There was one cautionary note, however.